FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia

Seminars in Hematology

Volumn 52, Issue 3, 2015, Pages 193-199

  Grunwald, Michael R ^a   Levis, Mark J ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BROMODOMAIN INHIBITOR; CD135 ANTIGEN; CPI 0610; CRENOLANIB; CYTARABINE; DAUNORUBICIN; GILTERITINIB; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; LESTAURTINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIDOSTAURIN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; PINOMETOSTAT; PLX 3397; PROTEIN TYROSINE KINASE INHIBITOR; QUIZARTINIB; SELUMETINIB; SORAFENIB; STEM CELL FACTOR; TRAMETINIB; UNCLASSIFIED DRUG; VOLASERTIB; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; PROTEIN KINASE INHIBITOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EVENT FREE SURVIVAL; FEVER; HAND FOOT SYNDROME; HISTONE MODIFICATION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MUTATION; SIGNAL TRANSDUCTION;

DRUG DESIGN; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84937414408     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.03.004     Document Type: Review

References (68)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Burnett A.K. Treatment of acute myeloid leukemia: are we making progress? Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2012, 2012:1-6.
3. Buchner T., Schlenk R.F., Schaich M., et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012, 30:3604-3610.
4. Levis M., Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003, 17:1738-1752.
5. Plowman G.D., Sudarsanam S., Bingham J., Whyte D., Hunter T. The protein kinases of Caenorhabditis elegans: a model for signal transduction in multicellular organisms. Proc Natl Acad Sci U S A 1999, 96:13603-13610.
6. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
7. Welch J.S., Ley T.J., Link D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
8. Grunwald M.R., Levis M.J. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 2013, 97:683-694.
9. Roboz G.J. Epigenetic targeting and personalized approaches for AML. ASH Education Program Book 2014, 2014:44-51.
10. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
11. Serve H., Krug U., Wagner R., et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013, 31:3110-3118.
12. Ravandi F., Alattar M.L., Grunwald M.R., et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121:4655-4662.
13. Wolleschak D., Schalk E., Krogel C., et al. Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. J. Hematol Oncol 2013, 6:39.
14. Macdonald D.A., Assouline S.E., Brandwein J., et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma 2013, 54:760-766.
15. Levis M.J., Perl A.E., Dombret H., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 673.
16. Cortes J.E., Perl A.E., Dombret H., et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 48.
17. Grunwald M.R., Levis M.J. Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?. Int J Hematol Oncol 2013, 2:9-11.
18. Smith C.C., Wang Q., Chin C.S., et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263.
19. Levis M., Brown P., Smith B.D., et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006, 108:3477-3483.
20. Levis M., Ravandi F., Wang E.S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117:3294-3301.
21. Smith B.D., Levis M., Beran M., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103:3669-3676.
22. Crump M., Hedley D., Kamel-Reid S., et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010, 51:252-260.
23. Zhang W., Konopleva M., Shi Y.X., et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008, 100:184-198.
24. Pratz K.W., Cho E., Levis M.J., et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010, 24:1437-1444.
25. Metzelder S., Wang Y., Wollmer E., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
26. Sharma M., Ravandi F., Bayraktar U.D., et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011, 17:1874-1877.
27. Metzelder S.K., Schroeder T., Finck A., et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012, 26:2353-2359.
28. Chen Y.B., Li S., Lane A.A., et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014, 20:2042-2048.
29. Sammons S.L., Pratz K.W., Smith B.D., Karp J.E., Emadi A. Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant. Am J Hematol 2014, 89:936-938.
30. Stone R.M., DeAngelo D.J., Klimek V., et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105:54-60.
31. Fischer T., Stone R.M., Deangelo D.J., et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010, 28:4339-4345.
32. Knapper S., Burnett A.K., Littlewood T., et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006, 108:3262-3270.
33. Pratz KW Cortes J, Roboz G.J., et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009, 113:3938-3946.
34. Cortes J.E., Kantarjian H., Foran J.M., et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013, 31:3681-3687.
35. Collins R., Kantarjian H.M., Levis M.J., et al. Clinical activity of crenolanib in patients with D835 mutant FLT3-positive relapsed/refractory acute myeloid leukemia. J Clin Oncol 2014, 32:5s. (suppl; abstr 7027).
36. Ravandi F., Cortes J.E., Jones D., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010, 28:1856-1862.
37. Röllig C., Müller-Tidow C., Hüttmann A., et al. Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. Blood (ASH Annual Meeting Abstracts) 2014, 124. abstract 6.
38. Stone R.M., Fischer T., Paquette R., et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia 2012, 26:2061-2068.
39. Strati P., Kantarjian H., Ravandi F., et al. Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol 2015, 90:276-281.
40. Knapper S., Hills R.K., Cavenagh J.D., et al. A randomised comparison of the sequential addition of the FLT3 inhibitor lestaurtinib (CEP701) to standard first line chemotherapy for FLT3-mutated acute myeloid leukemia: the UK experience. Blood (ASH Annual Meeting Abstracts) 2014, 124. abstract 3736.
41. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol 2006, 24:3904-3911.
42. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089.
43. Marcucci G., Geyer S., Zhao W., et al. Adding KIT inhibitor dasatinib to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor acute myeloid leukemia: results from CALGB 10801 (Alliance). Blood (ASH Annual Meeting Abstracts) 2014, 124. abstract 8.
44. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
45. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765-773.
46. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066.
47. Abbas S., Lugthart S., Kavelaars F.G., et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010, 116:2122-2126.
48. Stein E.M., Altman J.K., Collins R., et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzymes, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2014, 124. abstract 115.
49. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
50. Dohner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106:3740-3746.
51. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005, 352:254-266.
52. Falini B., Martelli M.P., Bolli N., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117:1109-1120.
53. Falini B., Gionfriddo I., Cecchetti F., Ballanti S., Pettirossi V., Martelli M.P. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?. Blood reviews 2011, 25:247-254.
54. Ley T.J., Mardis E.R., Ding L., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
55. Burnett A.K., Hills R.K., Milligan D., et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011, 29:369-377.
56. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
57. Schlenk R.F., Dohner K., Kneba M., et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009, 94:54-60.
58. Schlenk R.F., Döhner K., Krauter J., et al. All-trans retinoic acid improves outcome in younger adult patients with nucleophosmin-1 mutated acute myeloid leukemia: results of the AMLSG 07-04 randomized treatment trial. Blood (ASH Annual Meeting Abstracts) 2011, 118. abstract 80.
59. Schlenk R.F., Frohling S., Hartmann F., et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004, 18:1798-1803.
60. Burnett A.K., Hills R.K., Green C., et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010, 115:948-956.
61. Smith C.C., Shah N.P. The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia. American Society of Clinical Oncology Educational Book/ASCO. American Society of Clinical Oncology Meeting 2013, 313-318.
62. Piloto O., Wright M., Brown P., Kim K.T., Levis M., Small D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007, 109:1643-1652.
63. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
64. Yee K.W., Zeng Z., Konopleva M., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006, 12:5165-5173.
65. Rizzieri D.A., Feldman E., Dipersio J.F., et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008, 14:2756-2762.
66. Borthakur G., Popplewell L., Boyiadzis M., et al. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK1120212) in relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease. Blood (ASH Annual Meeting Abstracts) 2012, 120. abstract 677.
67. Jain N., Curran E., Iyengar N.M., et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014, 20:490-498.
68. Dohner H., Lubbert M., Fiedler W., et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood 2014, 124:1426-1433.